|
1
|
Coca SG, Singanamala S and Parikh CR:
Chronic kidney disease after acute kidney injury: A systematic
review and meta-analysis. Kidney Int. 81:442–448. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boor P, Ostendorf T and Floege J: Renal
fibrosis: Novel insights into mechanisms and therapeutic targets.
Nat Rev Nephrol. 6:643–656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Becker GJ and Hewitson TD: The role of
tubulointerstitial injury in chronic renal failure. Curr Opin
Nephrol Hypertens. 9:133–138. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wynn TA: Common and unique mechanisms
regulate fibrosis in various fibroproliferative diseases. J Clin
Invest. 117:524–529. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sulikowska B, Rutkowski B, Marszałek A and
Manitius J: The role of interstitial changes in the progression of
chronic kidney disease. Postepy Hig Med Dosw (Online). 69:830–837.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Levin A: Improving global kidney health:
International society of nephrology initiatives and the global
kidney health atlas. Ann Nutr Metab. 72 Suppl 2:S28–S32. 2018.
View Article : Google Scholar
|
|
7
|
Jager KJ and Fraser SDS: The ascending
rank of chronic kidney disease in the global burden of disease
study. Nephrol Dial Transplant. 32 Suppl_2:ii121–ii128. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jha V, Garcia-Garcia G, Iseki K, Li Z,
Naicker S, Plattner B, Saran R, Wang AY and Yang CW: Chronic kidney
disease: Global dimension and perspectives. Lancet. 382:260–272.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun YB, Qu X, Caruana G and Li J: The
origin of renal fibroblasts/myofibroblasts and the signals that
trigger fibrosis. Differentiation. 92:102–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cannito S, Novo E, di Bonzo LV, Busletta
C, Colombatto S and Parola M: Epithelial-mesenchymal transition:
From molecular mechanisms, redox regulation to implications in
human health and disease. Antioxid Redox Signal. 12:1383–1430.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meng XM, Nikolic-Paterson DJ and Lan HY:
TGF-β: The master regulator of fibrosis. Nat Rev Nephrol.
12:325–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu JH, He L, Zou ZM, Ding ZC, Zhang X,
Wang H, Zhou P, Xie L, Xing S and Yi CZ: A novel inhibitor of
homodimerization targeting MyD88 ameliorates renal interstitial
fibrosis by counteracting TGF-β1-induced EMT in vivo and in vitro.
Kidney Blood Press Res. 43:1677–1687. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bae E, Kim SJ, Hong S, Liu F and Ooshima
A: Smad3 linker phosphorylation attenuates Smad3 transcriptional
activity and TGF-β1/Smad3-induced epithelial-mesenchymal transition
in renal epithelial cells. Biochem Biophys Res Commun. 427:593–599.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bei K, Du Z, Xiong Y, Liao J, Su B and Wu
L: BMP7 can promote osteogenic differentiation of human periosteal
cells in vitro. Mol Biol Rep. 39:8845–8851. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singla DK, Singla R and Wang J: BMP-7
treatment increases M2 macrophage differentiation and reduces
inflammation and plaque formation in Apo E-/- Mice. PLoS One.
11:e01478972016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dudley AT, Lyons KM and Robertson EJ: A
requirement for bone morphogenetic protein-7 during development of
the mammalian kidney and eye. Genes Dev. 9:2795–2807. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Luo G, Hofmann C, Bronckers AL, Sohocki M,
Bradley A and Karsenty G: BMP-7 is an inducer of nephrogenesis, and
is also required for eye development and skeletal patterning. Genes
Dev. 9:2808–2820. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Almanzar MM, Frazier KS, Dube PH, Piqueras
AI, Jones WK, Charette MF and Paredes AL: Osteogenic protein-1 mRNA
expression is selectively modulated after acute ischemic renal
injury. J Am Soc Nephrol. 9:1456–1463. 1998.PubMed/NCBI
|
|
19
|
Ivanac-Janković R, Ćorić M, Furić-Čunko V,
Lovičić V, Bašić-Jukić N and Kes P: BMP-7 protein expression is
downregulated in human diabetic nephropathy. Acta Clin Croat.
54:164–168. 2015.PubMed/NCBI
|
|
20
|
Bramlage CP, Tampe B, Koziolek M, Maatouk
I, Bevanda J, Bramlage P, Ahrens K, Lange K, Schmid H, Cohen CD, et
al: Bone morphogenetic protein (BMP)-7 expression is decreased in
human hypertensive nephrosclerosis. BMC Nephrol. 11:312010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Klahr S and Morrissey J: Obstructive
nephropathy and renal fibrosis: The role of bone morphogenic
protein-7 and hepatocyte growth factor. Kidney Int Suppl.
87:S105–S112. 2003. View Article : Google Scholar
|
|
22
|
Zeisberg M and Kalluri R: Reversal of
experimental renal fibrosis by BMP7 provides insights into novel
therapeutic strategies for chronic kidney disease. Pediatr Nephrol.
23:1395–1398. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu Z, Zai-Chun X, Wun-Lun H and Yun-Yun Z:
BMP-7 attenuates TGF-β1-induced fibronectin secretion and apoptosis
of NRK-52E cells by the suppression of miRNA-21. Oncol Res.
23:147–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Celic T, Spanjol J, Grskovic A, Markic D,
Prebilic I, Fuckar Z and Bobinac D: Bone morphogenetic protein-7
reduces cold ischemic injury in rat kidney. Transplant Proc.
43:2505–2509. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yanagita M, Okuda T, Endo S, Tanaka M,
Takahashi K, Sugiyama F, Kunita S, Takahashi S, Fukatsu A,
Yanagisawa M, et al: Uterine sensitization-associated gene-1
(USAG-1), a novel BMP antagonist expressed in the kidney,
accelerates tubular injury. J Clin Invest. 116:70–79. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yanagita M: Balance between bone
morphogenetic proteins and their antagonists in kidney injury. Ther
Apher Dial. 11 Suppl 1:S38–S43. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Collette NM, Yee CS, Hum NR, Murugesh DK,
Christiansen BA, Xie L, Economides AN, Manilay JO, Robling AG and
Loots GG: Sostdc1 deficiency accelerates fracture healing by
promoting the expansion of periosteal mesenchymal stem cells. Bone.
88:20–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Murashima-Suginami A, Takahashi K, Sakata
T, Tsukamoto H, Sugai M, Yanagita M, Shimizu A, Sakurai T, Slavkin
HC and Bessho K: Enhanced BMP signaling results in supernumerary
tooth formation in USAG-1 deficient mouse. Biochem Biophys Res
Commun. 369:1012–1016. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tanaka M, Asada M, Higashi AY, Nakamura J,
Oguchi A, Tomita M, Yamada S, Asada N, Takase M, Okuda T, et al:
Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse
model of the progressive hereditary kidney disease Alport syndrome.
J Clin Invest. 120:768–777. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tanaka M, Endo S, Okuda T, Economides AN,
Valenzuela DM, Murphy AJ, Robertson E, Sakurai T, Fukatsu A,
Yancopoulos GD, et al: Expression of BMP-7 and USAG-1 (a BMP
antagonist) in kidney development and injury. Kidney Int.
73:181–191. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yisireyili M, Hayashi M, Wu H, Uchida Y,
Yamamoto K, Kikuchi R, Shoaib Hamrah M, Nakayama T, Wu Cheng X,
Matsushita T, et al: Xanthine oxidase inhibition by febuxostat
attenuates stress-induced hyperuricemia, glucose dysmetabolism, and
prothrombotic state in mice. Sci Rep. 7:12662017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Day RO, Kamel B, Kannangara DR, Williams
KM and Graham GG: Xanthine oxidoreductase and its inhibitors:
Relevance for gout. Clin Sci (Lond). 130:2167–2180. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chinchilla SP, Urionaguena I and
Perez-Ruiz F: Febuxostat for the chronic management of
hyperuricemia in patients with gout. Expert Rev Clin Pharmacol.
9:665–673. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sircar D, Chatterjee S, Waikhom R, Golay
V, Raychaudhury A, Chatterjee S and Pandey R: Efficacy of
febuxostat for slowing the GFR decline in patients with CKD and
asymptomatic hyperuricemia: A 6-month, double-blind, randomized,
placebo-controlled trial. Am J Kidney Dis. 66:945–950. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fahmi AN, Shehatou GS, Shebl AM and Salem
HA: Febuxostat exerts dose-dependent renoprotection in rats with
cisplatin-induced acute renal injury. Naunyn Schmiedebergs Arch
Pharmacol. 389:819–830. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee HJ, Jeong KH, Kim YG, Moon JY, Lee SH,
Ihm CG, Sung JY and Lee TW: Febuxostat ameliorates diabetic renal
injury in a streptozotocin-induced diabetic rat model. Am J
Nephrol. 40:56–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cao J, Li Y, Peng Y, Zhang Y, Li H, Li R
and Xia A: Febuxostat prevents renal interstitial fibrosis by the
activation of BMP-7 signaling and inhibition of USAG-1 expression
in rats. Am J Nephrol. 42:369–378. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Manson SR, Niederhoff RA, Hruska KA and
Austin PF: The BMP-7-Smad1/5/8 pathway promotes kidney repair after
obstruction induced renal injury. J Urol. 185 (6
Suppl):S2523–S2530. 2011. View Article : Google Scholar
|
|
39
|
Liu H, Xiong J, He T, Xiao T, Li Y, Yu Y,
Huang Y, Xu X, Huang Y, Zhang J, et al: High uric acid-induced
epithelial-mesenchymal transition of renal tubular epithelial cells
via the TLR4/NF-κB signaling pathway. Am J Nephrol. 46:333–342.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Song S, Qiu D, Luo F, Wei J, Wu M, Wu H,
Du C, Du Y, Ren Y, Chen N, et al: Knockdown of NLRP3 alleviates
high glucose or TGFB1-induced EMT in human renal tubular cells. J
Mol Endocrinol. 61:101–113. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zeisberg M, Hanai J, Sugimoto H, Mammolo
T, Charytan D, Strutz F and Kalluri R: BMP-7 counteracts
TGF-beta1-induced epithelial-to-mesenchymal transition and reverses
chronic renal injury. Nat Med. 9:964–968. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun J, Yin A, Zhao F, Zhang W and Lv J and
Lv J: Protection of tubular epithelial cells during renal injury
via post-transcriptional control of BMP7. Mol Cell Biochem.
435:141–148. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zeisberg M, Shah AA and Kalluri R: Bone
morphogenic protein-7 induces mesenchymal to epithelial transition
in adult renal fibroblasts and facilitates regeneration of injured
kidney. J Biol Chem. 280:8094–8100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Massagué J and Chen YG: Controlling
TGF-beta signaling. Genes Dev. 14:627–644. 2000.PubMed/NCBI
|
|
45
|
Yanagita M, Oka M, Watabe T, Iguchi H,
Niida A, Takahashi S, Akiyama T, Miyazono K, Yanagisawa M and
Sakurai T: USAG-1: A bone morphogenetic protein antagonist
abundantly expressed in the kidney. Biochem Biophys Res Commun.
316:490–500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Omori H, Kawada N, Inoue K, Ueda Y,
Yamamoto R, Matsui I, Kaimori J, Takabatake Y, Moriyama T, Isaka Y
and Rakugi H: Use of xanthine oxidase inhibitor febuxostat inhibits
renal interstitial inflammation and fibrosis in unilateral ureteral
obstructive nephropathy. Clin Exp Nephrol. 16:549–556. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hamasaki Y, Doi K, Okamoto K, Ijichi H,
Seki G, Maeda-Mamiya R, Fujita T and Noiri E:
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor
simvastatin ameliorates renal fibrosis through HOXA13-USAG-1
pathway. Lab Invest. 92:1161–1170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Peng L, He Q, Li X, Shuai L, Chen H, Li Y
and Yi Z: HOXA13 exerts a beneficial effect in albumin-induced
epithelial-mesenchymal transition via the glucocorticoid receptor
signaling pathway in human renal tubular epithelial cells. Mol Med
Rep. 14:271–276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee JH, Kim JH, Kim JS, Chang JW, Kim SB,
Park JS and Lee SK: AMP-activated protein kinase inhibits TGF-β-,
angiotensin II-, aldosterone-, high glucose-, and albumin-induced
epithelial-mesenchymal transition. Am J Physiol Renal Physiol.
304:F686–F697. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lee JY, Chang JW, Yang WS, Kim SB, Park
SK, Park JS and Lee SK: Albumin-induced epithelial-mesenchymal
transition and ER stress are regulated through a common ROS-c-Src
kinase-mTOR pathway: Effect of imatinib mesylate. Am J Physiol
Renal Physiol. 300:F1214–F1222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang S, Li Y, Song X, Wang X, Zhao C, Chen
A and Yang P: Febuxostat pretreatment attenuates myocardial
ischemia/reperfusion injury via mitochondrial apoptosis. J Transl
Med. 13:2092015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tsuda H, Kawada N, Kaimori JY, Kitamura H,
Moriyama T, Rakugi H, Takahara S and Isaka Y: Febuxostat suppressed
renal ischemia-reperfusion injury via reduced oxidative stress.
Biochem Biophys Res Commun. 427:266–272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nomura J, Busso N, Ives A, Matsui C,
Tsujimoto S, Shirakura T, Tamura M, Kobayashi T, So A and Yamanaka
Y: Xanthine oxidase inhibition by febuxostat attenuates
experimental atherosclerosis in mice. Sci Rep. 4:45542014.
View Article : Google Scholar : PubMed/NCBI
|
